AcelRx initiated its first Phase 3 medical study for ARX-01.

AcelRx commences dosing in second ARX-01 Stage 3 clinical trial for acute post-operative pain AcelRx Pharmaceuticals, Inc. Related StoriesInner ear damage brain warnings from nerve cellsDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixImmune submits Bertilimumab IND program to FDA for treatment of Bullous PemphigoidIn March 2012, AcelRx initiated its first Phase 3 medical study for ARX-01, a randomized, double-blind, placebo-managed efficacy and safety research comparing ARX-01 to placebo for post-operative pain control following major open up abdominal surgery. ‘We are extremely pleased to have our second ARX-01 Phase 3 medical trial underway. King added, ‘This year is an exciting time for AcelRx, with the delivery of top-series data from all three ARX-01 Phase 3 clinical trials expected by past due 2012 or early 2013.’..Study had been recruited through community outreach applications and advertising campaigns, whereas our patients were recruited from referral centers. In conclusion, in a study of adult outpatients with stable sickle cell disease, we found that the prevalence of pulmonary hypertension, as detected on initial echocardiographic screening and confirmed by correct heart catheterization, was 6 percent. Echocardiographic evaluation alone with the use of the tricuspid regurgitant velocity as a threshold criterion acquired a minimal positive predictive worth for pulmonary hypertension. The optimal approach for screening such patients for right cardiovascular catheterization remains uncertain..